Clinical Trials Logo

Adrenocortical Adenoma, clinical trials

View clinical trials related to Adrenocortical Adenoma,.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06344143 Not yet recruiting - Clinical trials for Mild Autonomous Cortisol Secretion (MACS)

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

MACS
Start date: July 1, 2024
Phase:
Study type: Observational

The aim of the proposed study is to estimate the incidence of Mild Autonomous Cortisol Secretion (MACS) in patients with Adrenal Incidentaloma (AI) and evaluate the available diagnostic tests to determine the most sensitive and specific combination of tests for assessing MACS from adrenal adenoma for prediction of the phenotype associated with cortisol excess. As well as following the patients for 4 years and see if anything changes.

NCT ID: NCT05927961 Not yet recruiting - Clinical trials for Primary Aldosteronism Due to Aldosterone Producing Adenoma

Spatial Proteomics Profiles of Aldosterone-producing Adenoma and Unilateral Hyperplasia

Start date: August 2023
Phase:
Study type: Observational

Primary aldosteronism (PA) is a common cause of secondary hypertension, which is characterized by excessive aldosterone production by the adrenal gland. Excessive aldosterone can significantly increase the risk of cardiovascular disease and stroke. Patients with aldosterone-producing adenoma (APA) or unilateral hyperplasia (UAH) can be cured by unilateral adrenalectomy. The adrenal cortex is the outer part of the adrenal gland and is subdivided into three layers- the zona glomerulosa, the zona fasciculata, and the zona reticularis. And the outermost layer is the zona glomerulosa, and it's full of cells that make the hormone aldosterone. Although it has been investigated that the main cause of APA or UAH is the mutations of different calcium ion channels, including KCNJ5, CACNA1D, CLCN2 et al, it is still unknown whether there are any other changes of other proteins in different layers. Therefore, the investigators designed the study to characterize the proteomics profiles of adrenal adenoma/hyperplasia leading to primary aldosterone and identify biomarkers for early identification of PA by using spatial proteomics. The samples from adrenal adenoma or hyperplasia will be collected and analyzed by spatial proteomics in Hangzhou Jingjie Biotechnology Co., Ltd. The differentially expressed proteins in different layers will be screened out between APA and UAH, APA and its adjacent normal tissues, and UAH and its adjacent normal tissues, respectively. And KEGG analysis will be conducted to determine enriched pathway in these differentially expressed protein, respectively.